Nivolumab trials for Melanoma Stage III

All Nivolumab trials · All Melanoma Stage III trials

Phase breakdown

Recruiting trials studying Nivolumab for Melanoma Stage III

• Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
  NCT04741997 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
  NCT04562129 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
  NCT05655312 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 13 locations
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
  NCT06295159 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
  NCT05652673 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Nivolumab for Melanoma Stage III?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.